A flash card for Enzon’s Abelcet makes unsubstantiated superiority claims and overstates its efficacy, the FDA says. A warning letter says the claims raise concerns because they suggest it is more effective than demonstrated and encourage its use before other options, even though it is a second-line agent.
FDA: Enzon’s Abelcet makes unsubstantiated superiority claims
A flash card for Enzon’s Abelcet makes unsubstantiated superiority claims and overstates its efficacy, the FDA says.
